Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR Annual Meeting 2026

Orum Therapeutics to Present New Preclinical Data on ORM-1153, a CD123-Targeting Degrader Antibody Conjugate, at the AACR ...
Business Wire

Payments Technology Leader Orum Launches ‘Monitor’ – The First-Ever Payments Portal Purpose Built To Optimize & Orchestrate Payment Operations For Enterprise Businesses

NEW YORK--(BUSINESS WIRE)--Orum, the innovative fintech that transforms payment technology for businesses by revolutionizing payment speed, certainty, and orchestration, today announced the launch of ...
Yahoo Finance

Orum Teams Up with Visa Direct to Launch Faster Payments

The collaboration enables U.S.-based customers to easily and quickly move money via Orum’s Deliver API and Visa Direct NEW YORK, February 26, 2025--(BUSINESS WIRE)--Orum, which transforms payment ...
Business Wire

Orum Therapeutics Secures Approximately US$100 Million to Accelerate Development of Leading Degrader Antibody Conjugate Programs to Treat Serious Diseases

Funding supports advancing therapeutic programs toward clinical development, expanding discovery across novel payload classes to accelerate next-generation degrader-antibody conjugate (DAC) programs ...
MM&M

BMS scoops up Orum Therapeutics’ blood, bone cancer drug for $100M

Bristol Myers Squibb picked up Orum Therapeutics’ blood and bone cancer drug ORM-6151 for $100 million upfront and up to $80 million in future milestones, the pharma giant announced Monday. ORM-6151 ...

Orum Achieves 36% Conversion Rate With Idomoo Personalized AI Video

Thanks to Lucas AI Video Creator, Orum created a high-quality personalized year in review at scale.NEW YORK--(BUSINESS WIRE)- ...